NASDAQ:ENVB

Biotechnology·Finance·NASDAQ:ENVB·News·Stock Market

Enveric Biosciences Stock Slips as Cash Questions Hang Over ENVB

Enveric Biosciences closed at $2.30 on Nasdaq Friday, down 0.86%, with a market cap near $8.5 million. The company’s last update was a May 19 release on preclinical safety data for EB-003. Its Q1 filing warned current cash won’t cover 12 months of operations. Enveric remains preclinical and has not announced new funding or product approvals.

May 29, 2026

Fortescue Ltd (FMG) and Qantas (QAN) Shares: Assessing Potential Blue Chip Investments on ASX
May 29, 2026, 4:20 PM EDT. Fortescue Ltd (ASX:FMG) share price has increased by 0.8% in early 2025, reflecting steady growth in the iron ore and exploration sectors. FMG focuses on iron ore production in Western Australia's Pilbara region, shipping over 190 million tonnes annually. It is expanding into copper, lithium, and rare earths to tap into rising demand linked to renewable energy. Fortescue reported a FY24 debt/equity ratio of 27.6%, a robust 30.2% return on equity (ROE), and an average 10.5% dividend yield, indicating strong financial health typical of a blue chip. Qantas Airways Ltd (ASX:QAN), Australia's largest airline, continues revenue and profit growth post-pandemic despite consumer trust challenges. Investors may consider FMG for steady income and QAN for growth potential based on their distinct business models and market positions.